Microsoft word - final program.doc

Final Program
International Conference on Myasthenia Gravis, Paris 2009
Organized by the EuroMyasthenia Network
December 1, 2009
Etiological, genetic, and immunological aspects
Chairs: A. Vincent and R. Mantegazza

9h00: Plenary Lecture: Aetiology of autoimmune diseases –JF. Bach
9h30: Is there a link between innate and autoimmunity in MG? – R. Mantegazza
9h50: Thymic changes in MG: Involvement of chemokines in thymic hyperplasia associated with an
inflammatory environment – R. Le Panse
10h10: BAFF and autoimmune disease S. Ragheb

10h30-10h50: Coffee break

10h50: Immune regulation defect in MG – S. Berrih-Aknin
11h10: Genetic factors in autoimmune MG: present status and challenges – H. J. Garchon
11h30: Role of AIRE deficiency in thymoma-MG – A. Marx
11h50: Thymic changes in MG patients– I. Leite
12h10-12h25: Cytokine production of B-cell culture of MG patients – V. Yilmaz
12h30-14h00: Lunch break
Muscle pathophysiology
Chairs: B. Eymard and S. Fuchs

14h00: Plenary Lecture: Dok-7, Musk, and the development of the neuromuscular junction – Y.

14h30: The role of AChR associated proteins in autoimmune MG – P. Martinez
14h50: Pathogenic mechanisms underlying synaptic dysfunction in congenital myasthenic syndromes
D. Beeson
15h10: Identification of a mutation in agrin that causes congenital myasthenia and affects synapse
function – D. Hantai
15h30: Anti-AChR antibodies increase IL-6 production by myoblasts and myotubes in vitro –
S. Bougoin
15h45-16h00: Coffee break
Experimental therapy
Chairs: S. Tzartos and H. Kaminski

16h00: Plenary Lecture: Therapeutic approaches for MG studied in animal models – M. Souroujon
16h30: Complement-targeted therapy for MG – E. Tuzun
16h50: Mobilization of regulatory immune cells utilizing GM-CSF in EAMG – M. Meriggioli
17h10: Cholinergic anti-inflammatory signaling through α7 nicotinic acetylcholine receptor – T.

17h30: Development of safe and effective oral tolerogen for MG – S. H. Im
17h45-19h00: Poster session I
December 2, 2009
Diagnosis issues and clinical therapy
Chairs: M. De Baets and A. Melms

9h00: Plenary lecture: An update on diagnosis issues – A. Vincent
9h30: Recombinant antigenic domains for the study, diagnosis and treatment of MG – S. Tzartos
9h50: Status of the Trial for Thymectomy in nonthymomatous MG Patients Receiving Prednisone
(MGTX) – H. Kaminski
10h10: Mycophenolate Mofetil (MMF) in AChR-antibody Positive MG: Outcomes in 102 patients –
D. Sanders
10h30: Refractory MG and rituximab: long term follow-up of three patients and the “FORCE” trial –
O. Benveniste

10h50: Classifying seronegative MG: a population based study – A. Carr
11h05-12h30: Poster session II with coffee break
12h30-14h00: Lunch break
Public Health aspects
Chairs: J. Verschuuren and A. Kostera –Pruszczyk

14h00: Plenary lecture: Myasthenia Gravis: from functioning and disability evaluation towards new
healthcare approaches – A. Raggi
14h30: Long-term treatment in MG: A review – A. Evoli
14h50: MG in the elderly – J. Aarli
A questionnaire for assessing the impact of socio-economic factors in MG – A. Maniaol
The EuroMyasthenia project: What has it brought to the MG community? – N. Kerlero de

15h50: Clinical and serological analysis of 175 patients with MG in Hungary Z. Illes
16h05-16h30: Coffee break
16h30-18h00: Session dedicated to interactions between clinicians, scientists
and patients
Medical panel: A. Evoli, A. Kostera-Pruszczyk, D. Sanders and C. Tallaksen

A medical panel will answer questions submitted by patients prior to the meeting through the
conference website accessible via



PUBLICATIONS Epidémiologie Moléculaire du Cancer IRCAD-EITS • 1, place de l’Hôpital • Hôpitaux Universitaires • 67091 Strasbourg Cedex • Tél. +33 3 88 11 90 00 • Fax +33 3 88 11 91 99E-mail : [email protected] – SIRET 391 854 791 00012 – Code APE 731Z – N° d’id. intracom. FR 45 391 854 791 00012 PUBLICATIONS 1. Epidémiologie Moléculaire du Cancer 1. Burnouf

Mediapart "48h"

Directeur de la publication : Edwy Plenel«Après le Mediator, le scandale à venir est celui des traite-ments anti-Alzheimer !»Par Sylvain BourmeauArticle publié le mardi 04 janvier 2011Lacouverture de l’affaire du Mediator, ce médicament des labo-C’est un médecin qui écrit après le passage dans son cabinet d’unratoires Servier rendu responsable de la mort de 500 à 2.000 p

Copyright © 2009-2018 Drugs Today